Fairvoy Private Wealth LLC Takes Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Fairvoy Private Wealth LLC purchased a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm purchased 4,416 shares of the medical research company’s stock, valued at approximately $2,297,000.

A number of other large investors also recently modified their holdings of the company. Sumitomo Mitsui DS Asset Management Company Ltd raised its holdings in shares of Thermo Fisher Scientific by 2.2% during the 4th quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 55,588 shares of the medical research company’s stock valued at $28,919,000 after buying an additional 1,213 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. raised its holdings in shares of Thermo Fisher Scientific by 1.3% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,119,017 shares of the medical research company’s stock valued at $582,146,000 after buying an additional 14,576 shares in the last quarter. Strategic Financial Concepts LLC purchased a new position in shares of Thermo Fisher Scientific during the 4th quarter valued at about $127,742,000. Leo Wealth LLC raised its holdings in shares of Thermo Fisher Scientific by 1.5% during the 4th quarter. Leo Wealth LLC now owns 1,946 shares of the medical research company’s stock valued at $1,012,000 after buying an additional 29 shares in the last quarter. Finally, Hedeker Wealth LLC raised its holdings in shares of Thermo Fisher Scientific by 5.9% during the 4th quarter. Hedeker Wealth LLC now owns 7,534 shares of the medical research company’s stock valued at $3,919,000 after buying an additional 417 shares in the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have commented on TMO shares. Royal Bank of Canada decreased their price target on Thermo Fisher Scientific from $767.00 to $718.00 and set an “outperform” rating on the stock in a research note on Thursday, October 24th. Wells Fargo & Company lifted their price target on Thermo Fisher Scientific from $660.00 to $680.00 and gave the stock an “overweight” rating in a research note on Friday, January 31st. Robert W. Baird decreased their price target on Thermo Fisher Scientific from $632.00 to $622.00 and set an “outperform” rating on the stock in a research note on Thursday, October 24th. Morgan Stanley lifted their price target on Thermo Fisher Scientific from $647.00 to $678.00 and gave the stock an “overweight” rating in a research note on Friday, January 31st. Finally, Bernstein Bank lifted their price objective on Thermo Fisher Scientific from $565.00 to $625.00 and gave the stock a “market perform” rating in a research report on Tuesday, October 22nd. Four equities research analysts have rated the stock with a hold rating and nineteen have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $658.00.

Thermo Fisher Scientific Trading Down 1.8 %

NYSE TMO opened at $571.75 on Friday. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59. The stock’s 50 day moving average is $545.51 and its 200 day moving average is $571.95. Thermo Fisher Scientific Inc. has a twelve month low of $493.30 and a twelve month high of $627.88. The firm has a market capitalization of $218.70 billion, a PE ratio of 34.59, a P/E/G ratio of 4.06 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, topping the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. Research analysts forecast that Thermo Fisher Scientific Inc. will post 23.29 earnings per share for the current fiscal year.

Thermo Fisher Scientific announced that its board has approved a share repurchase plan on Friday, November 15th that permits the company to buyback $4.00 billion in shares. This buyback authorization permits the medical research company to reacquire up to 2% of its stock through open market purchases. Stock buyback plans are usually an indication that the company’s board believes its shares are undervalued.

Insider Transactions at Thermo Fisher Scientific

In other news, CFO Stephen Williamson sold 9,825 shares of the business’s stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total value of $5,753,421.75. Following the completion of the transaction, the chief financial officer now owns 27,296 shares in the company, valued at $15,984,264.64. The trade was a 26.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Gianluca Pettiti sold 300 shares of the company’s stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total value of $175,677.00. Following the sale, the executive vice president now owns 16,363 shares of the company’s stock, valued at approximately $9,582,009.17. This trade represents a 1.80 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 20,125 shares of company stock worth $11,231,699 over the last quarter. 0.34% of the stock is currently owned by insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.